Anastasia Katsoula, MD, of Greece-based Aristotle University of Thessaloniki, and colleagues conducted a meta-analysis of 12 studies with 6,204 patients. Researchers deemed seven studies as high or unclear risk of bias. They measured fecal immunochemical tests’ diagnostic performance.
Here’s what they found:
1. Researchers found FIT for CRC sensitivity was 93 percent, with an average specificity of 91 percent.
2. FIT for CRC had a positive likelihood of 10.30 and a negative likelihood ratio of 0.08.
3. Average sensitivity of FIT for advanced neoplasia was 48 percent, with an average specificity of 93 percent.
4. FIT for advanced neoplasia had a positive likelihood of 6.55 and a negative likelihood of 0.57.
5. Researchers conducted a subgroup analyses. It indicated FIT cutoff values between 15- and 25-μg/g feces provided the best combination for CRC diagnosis.
Researchers concluded, “The FIT has high overall diagnostic accuracy for CRC but moderate accuracy for AN in patients at above-average personal or familial risk. Heterogeneity and wide confidence intervals limit the trustworthiness of our findings.”
More articles on gastroenterology:
GI leader to know: Dr. David Schwartz of Vermont Gastroenterology
Exact Sciences pockets $238M from secondary stock sale — 3 key notes
Clarivate Analytics ranks AGA’s flagship magazine highest of 79 journals
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
